申请人:Sumitomo Dainippon Pharma Co., Ltd.
公开号:US10898469B2
公开(公告)日:2021-01-26
The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Q1 represents a C6-10 aryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R3, independently when multiple, represent(s) a halogen atom or the like; R1 and R2 independently represent a hydrogen atom or the like; W1 represents a C1-4 alkylene group (said group may be substituted by 1-3 fluorine atoms or C3-7 cycloalkyls); W2 represents —NR4aC(O)— or the like (where R4a represents a hydrogen atom or C1-6 alkyl group); and ring Q2 represents a C6-10 arylgroup or the like]
该发明涉及一种由式(1)表示的咪唑酰胺衍生物,该衍生物对癌细胞球形成能力具有显著的抑制作用,并且可作为一种口服抗肿瘤剂或其药理学上可接受的盐。【在该式中,环Q1代表C6-10芳基或类似物;m代表0、1、2、3、4或5;R3,当多个时,独立地代表卤原子或类似物;R1和R2独立地代表氢原子或类似物;W1代表C1-4烷基(该基团可被1-3氟原子或C3-7环烷基取代);W2代表—NR4aC(O)—或类似物(其中R4a代表氢原子或C1-6烷基);环Q2代表C6-10芳基或类似物】